The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Amado et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [22]
In the citing paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
In the citing paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Cited by
Sorted by citations
Items 701–800 of 1,014
Solassol, J., Ramos, J., Lopez‐Crapez, E., Saifi, M., Mangé, A., Vianès, E., Lamy, P., Costes, V., & Maudelondé, T. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12053191 · Cited by 59
Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas
Raghav, K. P. S., Shetty, A. V., Kazmi, S. M. A., Zhang, N., Morris, J. S., Taggart, M. W., Fournier, K. F., Royal, R. E., Mansfield, P. F., Eng, C., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0186 · Cited by 54
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 60
Davidson, C. J., Zeringer, E., Champion, K. J., Gauthier, M. L., Wang, F., Boonyaratanakornkit, J., Jones, J. R., & Schreiber, E. H. (2012) · BioTechniques · doi:10.2144/000113913 · Cited by 56
Riely, G. J., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080105 · Cited by 58
Circulating tumor cells in colorectal cancer patients
Torino, F., Bonmassar, E., Bonmassar, L., Vecchis, L. D., Barnabei, A., Zuppi, C., Capoluongo, E., & Aquino, A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.007 · Cited by 57
Glimelius, B. L. G., & Cavalli‐Björkman, N. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640828 · Cited by 57
Role of cMET in the Development and Progression of Colorectal Cancer
Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 59
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Mazard, T., Causse, A., Simony-Lafontaine, J., Leconet, W., Vié, N., Torro, A., Jarlier, M., Evrard, A., Rio, M. D., Assénat, E., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0966 · Cited by 57
Adjuvant treatment of colorectal cancer.
Carrato, A. (2008) · PubMed Central · Cited by 57
Precision medicine, genomics and drug discovery: Table 1.
Cardon, L. R., & Harris, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw246 · Cited by 58
Association between clinicopathological characteristics and RAS mutation in colorectal cancer
Rimbert, J., Tachon, G., Junca, A., Villalva, C., Karayan, L., & Tougeron, D. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.119 · Cited by 58
Jauhri, M., Bhatnagar, A., Gupta, S., BP, M., Minhas, S., Shokeen, Y., & Aggarwal, S. (2017) · Tumor Biology · doi:10.1177/1010428317692265 · Cited by 57
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Sastre, J., Massutí, B., Pulido, G., Guillén‐Ponce, C., Benavides, M., Manzano, J. L., Reboredo, M., Rivera, F., Grávalos, C., Safont, M. J., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.013 · Cited by 56
Rubinson, D. A., Höchster, H. S., Ryan, D. P., Wolpin, B. M., McCleary, N. J., Abrams, T. A., Chan, J. A.-W., Iqbal, S., Lenz, H. J., Lim, D. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9956-5 · Cited by 56
Hsieh, L., Er, T., Chen, C.-C., Hsieh, J., Chang, J., & Liu, T. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.04.029 · Cited by 57
In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
Verma, S., McLeod, D., Batist, G., Robidoux, A., Martins, I., & Mackey, J. R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0278 · Cited by 56
Impact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57
Autophagy: novel action of panitumumab in colon cancer.
Giannopoulou, E., Antonacopoulou, A. G., Matsouka, P., & Kalofonos, H. P. (2009) · PubMed · Cited by 56
Lièvre, A., Samalin, E., Mitry, E., Assénat, E., Gestin-Boyer, C., Lepère, C., Bachet, J., Portales, F., Vaillant, J.-N., Ychou, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-347 · Cited by 56
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 56
Wang, J., Yi, Y., Xiao, Y., Lin, D., Liang, L., Teng, L., Ying, J. M., Lu, T., Liu, Y., Guan, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0212-1 · Cited by 56
Benson, A. B., Arnoletti, J. P., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Dilawari, R. A., Engstrom, P. F., Enzinger, P. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0104 · Cited by 56
Kumar, S. S., Price, T. J., Mohyieldin, O., Borg, M., Townsend, A. R., & Hardingham, J. E. (2014) · Europe PMC (PubMed Central) · Cited by 56
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
Samalin, E., Bouché, O., Thézenas, S., François, É., Adenis, A., Bennouna, J., Taı̈eb, J., Desseigne, F., Seitz, J. F., Conroy, T., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.813 · Cited by 55
KRAS Testing: A Tool for the Implementation of Personalized Medicine
Shackelford, R. E., Whitling, N. A., McNab, P. M., Japa, S., & Coppola, D. (2012) · Genes & Cancer · doi:10.1177/1947601912460547 · Cited by 55
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region
Sebio, A., Paré, L., Páez, D., Salazar, J., González, A., Sala, N., del Río, E., Martín-Richard, M., Tobeña, M., Barnadas, A., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835d9b0b · Cited by 56
Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer
Cimino, G. D., Pan, C.-X., & Henderson, P. T. (2013) · Bioanalysis · doi:10.4155/bio.12.325 · Cited by 58
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
García‐Foncillas, J., & Díaz‐Rubio, E. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0551-3 · Cited by 55
High expression of Beclin-1 predicts favorable prognosis for patients with colorectal cancer
Yang, Z., Ghoorun, R. A., Fan, X., Wu, P., Bai, Y., Li, J., Chen, H., Wang, L., & Wang, J. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.06.014 · Cited by 55
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 57
Pharmacogenetics: implementing personalized medicine.
Mini, E., & Nobili, S. (2009) · PubMed Central · Cited by 55
Takegawa, N., & Yonesaka, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.001 · Cited by 55
Cancer biomarker determination by resonance energy transfer using functional fluorescent nanoprobes
Das, P., Sedighi, A., & Krull, U. J. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.07.060 · Cited by 58
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 56
Cuneo, K. C., Nyati, M. K., Ray, D., & Lawrence, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.002 · Cited by 57
Zlobec, I., Molinari, F., Kovac, M., Bihl, M., Altermatt, H. J., Diebold, J., Frick, H., Germer, M., Horcic, M., Montani, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605452 · Cited by 54
Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 54
Schwarz, R. E., Berlin, J. D., Lenz, H. J., Nordlinger, B., Rubbia‐Brandt, L., & Choti, M. A. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00558.x · Cited by 54
Marzi, L., Combès, E., Vié, N., Ayrolles-Torro, A., Tosi, D., Désigaud, D., Pérez-Gracia, E., Larbouret, C., Montagut, C. O., Iglesias, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.313 · Cited by 53
Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
Taı̈eb, J., Balogoun, R., Malicot, K. L., Tabernero, J. M., Mini, E., Folprecht, G., Laethem, J. V., Emile, J.-F., Mulot, C., Fratté, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw687 · Cited by 54
Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR
Decraene, C., Silveira, A. B., Bidard, F., Vallée, A., Michel, M., Melaabi, S., Vincent‐Salomon, A., Saliou, A., Houy, A., Milder, M., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272518 · Cited by 54
Levin-Sparenberg, E., Bylsma, L. C., Lowe, K. A., Sangaré, L. R., Fryzek, J. P., & Alexander, D. D. (2020) · Gastroenterology Research · doi:10.14740/gr1167 · Cited by 53
Hutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 57
Garrido‐Laguna, I., Hong, D. S., Jankú, F., Nguyen, L. M., Falchook, G. S., Fu, S., Wheler, J. J., Luthra, R., Naing, A., Wang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038033 · Cited by 52
Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S. R., Stiuso, P., Ciardiello, F., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.756469 · Cited by 53
Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., Kähler, G. F. B. A., Kienle, P., Post, S., Wenz, F. K., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.043 · Cited by 53
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
Yanus, G. A., Belyaeva, A. V., Ivantsov, A. O., Kuligina, E. S., Suspitsin, E. N., Mitiushkina, N. V., Алексахина, С. Н., Iyevleva, A. G., Zaitseva, O. A., Yatsuk, O. S., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0686-5 · Cited by 53
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer
Alexopoulou, D. K., Papadopoulos, I. N., & Scorilas, A. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.03.002 · Cited by 53
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
Zlobec, I. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i38.4823 · Cited by 52
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 53
Targeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 54
Laboratory methods forKRASmutation analysis
Anderson, S. M. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.42 · Cited by 53
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 56
Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs
Lizarbe, M. A., Calle-Espinosa, J., Fernández-Lizarbe, E., Fernández‐Lizarbe, S., Robles-Ramos, M. Á., Olmo, N., & Turnay, J. (2017) · BioMed Research International · doi:10.1155/2017/7354260 · Cited by 55
New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 59
Peeters, M., BALFOUR, J., & Arnold, D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03717.x · Cited by 52
Self-citationOncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17
Van Schaeybroeck, S., Kyula, J. N., Fenton, A., Fenning, C. S., Sasazuki, T., Shirasawa, S., Longley, D. B., & Johnston, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0714 · Cited by 51
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 54
Update on current problems in colorectal liver metastasis
Chakedis, J., Squires, M. H., Beal, E. W., Hughes, T. M., Lewis, H. L., Paredes, A. Z., Al-Mansour, M. R., Sun, S., Cloyd, J. M., & Pawlik, T. M. (2017) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2017.10.002 · Cited by 52
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 52
Lee, S., Brophy, V. H., Cao, J., Velez, M., Hoeppner, C., Soviero, S., & Lawrence, H. J. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1180-0 · Cited by 52
A comparability study of 5 commercial KRAS tests
Oliner, K. S., Juan, T., Suggs, S., Wolf, M., Sarosi, I., Freeman, D. J., Gyuris, T., Baron, W., Bakker, A., Parker, A. N., et al. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-23 · Cited by 52
Self-citationYang, M.-J., Chiu, H., Wang, H., Yen, L.-C., Tsao, D., Hsiao, C.-P., Chen, Y., Wang, J., & Lin, S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0831-8 · Cited by 52
Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer
Grothey, A. A., & Lenz, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4194 · Cited by 52
RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy
Osumi, H., Shinozaki, E., Suenaga, M., Matsusaka, S., Konishi, T., Akiyoshi, T., Fujimoto, Y., Nagayama, S., Fukunaga, Y., Ueno, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30106 · Cited by 52
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 54
Adverse kidney effects of epidermal growth factor receptor inhibitors
Izzedine, H., & Perazella, M. A. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw467 · Cited by 54
Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., Ang, A. L., Bach, B. A., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3377 · Cited by 52
Self-citationKato, S., Schwaederlé, M. C., Fanta, P. T., Okamura, R., Leichman, L., Lippman, S. M., Lanman, R. B., Raymond, V. M., Talasaz, A., & Kurzrock, R. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00158 · Cited by 52
Ciardiello, F., Adams, R., Tabernero, J., Seufferlein, T., Taieb, J., Moiseyenko, V., Ma, B., Lopez, G., Vansteenkiste, J. F., Esser, R., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0279 · Cited by 53
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 56
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.
Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., & Cavenee, W. K. (2013) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2013.04.003 · Cited by 53
Sakitani, K., Hirata, Y., Hikiba, Y., Hayakawa, Y., Ihara, S., Suzuki, H., Suzuki, N., Serizawa, T., Kinoshita, H., Sakamoto, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1789-5 · Cited by 53
Terahertz spectroscopy of oligonucleotides in aqueous solutions
Tang, M., Huang, Q. Y., Wei, D., Zhao, G., Chang, T., Kou, K., Wang, M., Du, C., Fu, W., & Cui, H. (2015) · Journal of Biomedical Optics · doi:10.1117/1.jbo.20.9.095009 · Cited by 51
Buiting, H. M., Terpstra, W. E., Dalhuisen, F., Gunnink-Boonstra, N., Sonke, G. S., & den Hartogh, G. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077959 · Cited by 51
Tunce, T., Özgün, A., Emi̇rzeoglu, L., Çelik, S., Bilgi, O., & Karagöz, B. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.15.6421 · Cited by 51
Sidhu, R., Rong, A., & Dahlberg, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2502 · Cited by 53
Chang, D. Z., Kumar, V. S., Ma, Y., Li, K., & Kopetz, S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-18 · Cited by 52
Self-citationFool’s gold, lost treasures, and the randomized clinical trial
Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51
Vickers, M. M., Karapetis, C. S., Tu, D., O’Callaghan, C. J., Price, T. J., Tebbutt, N. C., van Hazel, G., Shapiro, J. D., Pavlakis, N., Gibbs, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds577 · Cited by 51
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside
Rodon, J. A., Pérez-García, J. M., & Kurzrock, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0117 · Cited by 50
Pietrantonio, F., Cremolini, C., Aprile, G., Lonardi, S., Orlandi, A., Mennitto, A., Berenato, R., Antoniotti, C., Casagrande, M., Marsico, V. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0171 · Cited by 54
Ciardiello, F., Tejpar, S., Normanno, N., Mercadante, D., Teague, T., Wohlschlegel, B., & Cutsem, E. V. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0181-x · Cited by 51
Mutation spectra of RAS gene family in colorectal cancer
Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 51
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Kim, B., Kim, J. M., Kang, G. H., Chang, H. J., Kang, D. W., Kim, J. H., Bae, J. M., Seo, A. N., Park, H. S., Kang, Y. K., et al. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.09.28 · Cited by 56
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 52
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Spindler, K. G., Pallisgaard, N., Appelt, A. L., Andersen, R. F., Schou, J. V., Nielsen, D. L., Pfeiffer, P., Yilmaz, M., Johansen, J. S., Høgdall, E. V. S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.118 · Cited by 51
Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
Li, F., Lin, Y., Li, R., Shen, X., Xiang, M., Xiong, G., Zhang, K., Xia, T., Guo, J., Miao, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1165666 · Cited by 54
Grundberg, I., Kiflemariam, S., Mignardi, M., Imgenberg‐Kreuz, J., Edlund, K., Micke, P., Sundström, M., Sjöblom, T., Botling, J., & Nilsson, M. F. (2013) · Oncotarget · doi:10.18632/oncotarget.1527 · Cited by 50
MicroRNAs targeting EGFR signalling pathway in colorectal cancer
Mlčochová, J., Vychytilova‐Faltejskova, P., Němeček, R., Svoboda, M., & Slabý, O. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1470-9 · Cited by 50
Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
Feng, Q. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4263 · Cited by 49
Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab
Moon, C., Chae, Y. K., & Lee, J. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009181 · Cited by 50
Metadata
- Authors
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
- Affiliations
- Ghent University Hospital (BE)
- Amgen (United States) (US)
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1626-1634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106789440
- Cited by
- 3,207
- References
- 38
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
- FWCI
- 169.59
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-06-14)
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
- MeSH terms
- Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
